PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 122 filers reported holding PMV PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.67 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,767,046 | -2.9% | 4,033,721 | -1.0% | 0.00% | 0.0% |
| Q2 2023 | $25,512,656 | +33.6% | 4,075,504 | +1.8% | 0.00% | +50.0% |
| Q1 2023 | $19,094,000 | +53474.6% | 4,002,884 | -2.3% | 0.00% | -60.0% |
| Q4 2022 | $35,640 | -99.9% | 4,096,551 | -13.0% | 0.01% | -37.5% |
| Q3 2022 | $56,003,000 | -20.1% | 4,706,099 | -4.3% | 0.01% | -20.0% |
| Q2 2022 | $70,100,000 | +5.0% | 4,919,323 | +53.5% | 0.01% | +25.0% |
| Q1 2022 | $66,739,000 | -8.8% | 3,205,487 | +1.2% | 0.01% | 0.0% |
| Q4 2021 | $73,164,000 | +35.9% | 3,167,222 | +75.3% | 0.01% | +14.3% |
| Q3 2021 | $53,852,000 | -4.1% | 1,807,092 | +10.0% | 0.01% | 0.0% |
| Q2 2021 | $56,127,000 | +82.4% | 1,643,064 | +75.7% | 0.01% | +75.0% |
| Q1 2021 | $30,765,000 | +1248.2% | 935,390 | +2421.3% | 0.00% | – |
| Q4 2020 | $2,282,000 | +500.5% | 37,099 | +271.0% | 0.00% | – |
| Q3 2020 | $380,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |